Your browser doesn't support javascript.
loading
Flow-diverter silk stent for the treatment of intracranial aneurysms: 1-year follow-up in a multicenter study.
Berge, J; Biondi, A; Machi, P; Brunel, H; Pierot, L; Gabrillargues, J; Kadziolka, K; Barreau, X; Dousset, V; Bonafé, A.
Affiliation
  • Berge J; Department of Neuroradiology, University Hospital, Bordeaux Cedex, France. jerome.berge@chu-bordeaux.fr
AJNR Am J Neuroradiol ; 33(6): 1150-5, 2012 Jun.
Article de En | MEDLINE | ID: mdl-22300924
ABSTRACT
BACKGROUND AND

PURPOSE:

FD stent placement is a promising therapy for challenging intracranial aneurysms. Long-term evaluations about angiographic and morphologic results are still missing. This is the aim of this multicenter series. MATERIALS AND

METHODS:

We report our experience and 1-year FU in a retrospective chart review of 65 consecutive subjects with 77 unruptured or recanalized aneurysms that were treated with Silk FD stents at 6 centers in France. Both angiographic and clinical results were recorded before treatment and at 6 and 12 months after treatment. At the 12-month FU, relationships between angiographic aneurysm occlusion and shrinkage of the thrombosed aneurysm sac were evaluated.

RESULTS:

Stent deployment was achieved in 64 cases (98.5%) and failed in 1 case (1.5%). Seven misdeployments of the Silk stent caused the occlusion of 6 parent arteries. Overall acute/subacute procedural morbidity was 7.7%, and mortality was zero. Delayed complications were observed in 10.9% of subjects. At the 6-month FU, permanent morbidity was 7.8% and mortality was 3%. Complete occlusion occurred within 6 months in 68% of aneurysms and within 12 months after treatment in 84.5% of aneurysms. At the 12-month FU, in angiographically complete occluded aneurysms, MR imaging/CT analysis showed the complete disappearance of the thrombosed aneurysm in 30% of cases and partial shrinkage in 52%; furthermore, thrombosed aneurysms were stable in 11% of cases and enlarged in 7%.

CONCLUSIONS:

The Silk stent is an effective tool for the treatment of challenging aneurysms because it allows complete occlusion in most cases 1 year after treatment. Permanent morbidity was 7.8%, and mortality was 3%.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Prothèse vasculaire / Endoprothèses / Anévrysme intracrânien / Embolisation thérapeutique Type d'étude: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: AJNR Am J Neuroradiol Année: 2012 Type de document: Article Pays d'affiliation: France

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Prothèse vasculaire / Endoprothèses / Anévrysme intracrânien / Embolisation thérapeutique Type d'étude: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: AJNR Am J Neuroradiol Année: 2012 Type de document: Article Pays d'affiliation: France
...